Safety and immunogenicity of the oral E. coli K12-S. flexneri 2a vaccine (EcSf2a-2) among Israeli soldiers

Cohen, Dani; Ashkenazi, Shai; Green, Manfred S.; Yavzori, Miri; Orr, Nadav; Slepon, Raphael; Lerman, Yehuda; Robin, Guy; Ambar, Ruhama; Block, Colin; Taylor, David N.; Hale, Thomas L.; Sadoff, Jerald C.; Wiener, Michael

doi:10.1016/0264-410x(94)90153-8

Cited by 9 publications

(6 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mean age (range) of the subjects was 23 (19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35)(36)(37)(38) years with a slightly higher mean age in the 10 g group (Table 1). All subjects had a negative Shigella agglutination test at screening.…”

Section: Baseline Datamentioning

confidence: 97%

“…Alternatively, several researchers have chemically conjugated purified Shigella lipopolysaccharides (LPS) to a protein carrier [21]. These conjugates were parentally administrated and were shown to be safe, immunogenic and efficacious against disease in vaccinated volunteers and in field trials in the Israeli Defence Forces, respectively [22,23]. Subsequent studies showed promising results of conjugate vaccines in adults and children, but not in infants [24][25][26][27].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: A single blind, partially randomized Phase I study

Hatz

Bally

Rohrer³

et al. 2015

Vaccine

View full text Add to dashboard Cite

Section: Baseline Datamentioning

confidence: 97%

Section: Introductionmentioning

confidence: 99%

Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: A single blind, partially randomized Phase I study

Hatz

Bally

Rohrer³

et al. 2015

Vaccine

View full text Add to dashboard Cite

“…A strong correlation between preexisting IgG anti-LPS serum antibodies and acquired natural immunity against shigellosis was demonstrated previously (6,7). In immunogenicity studies of candidate Shigella vaccines, a significant rise in serum antibodies to homologous LPS was used as evidence for stimulation of immunocompetent cells (4,13,21). A few studies have shown that antibodies to various bacterial antigens can be detected in urine after natural infection of the urinary tract or other mucosal sites, or after vaccination (1,8,11,14,18,20), and that at least part of these antibodies are of mucosal origin (11,18).…”

mentioning

confidence: 77%

“…The assays were performed in microtitration plates (Costar, Cambridge, Mass.) as previously described for serum antibody detection (4,5). LPSs extracted by the phenol-water method (22) from clinical isolates of S. sonnei (form 1) and S. flexneri 2a were used as antigens.…”

Section: Methodsmentioning

confidence: 99%

Detection of antibodies to Shigella lipopolysaccharide in urine after natural Shigella infection or vaccination

Cohen

Orr

Robin

et al. 1996

Clin Diagn Lab Immunol

View full text Add to dashboard Cite

The purpose of the present study was to explore the possibility of detecting antibodies to Shigella sonnei lipopolysaccharide (LPS) in urine after infection or vaccination. Urinary immunoglobulin A (IgA) and IgG antibodies and specific IgA secretory protein against S. sonnei LPS were measured by enzyme-linked immunosorbent assay (ELISA), after adjustment for urine concentration. A significant antibody level was defined as one above a cutoff value calculated from the geometric mean + 2 standard deviations of urinary anti-S. sonnei LPS levels in 43 healthy hepatitis B vaccinees (controls). Of 11 culture-proven cases of S. sonnei shigellosis, at convalescence 9 (82%) had significantly elevated levels of urinary antibodies to the homologous LPS. The S. sonnei conjugate vaccine, composed of S. sonnei O-specific polysaccharide covalently bound to recombinant exoprotein A of Pseudomonas aeruginosa, elicited a significant urine IgA or IgG anti-LPS response in 60% (6 of 10), 56% (9 of 16) 43% (16 of 37), and 14% (3 of 21) of the volunteers at 2 weeks, 6 weeks, 6 months, and 12 months after vaccination, respectively. The specificity of the urine antibody response to S. sonnei LPS was documented by the total lack of response in subjects who received parenteral Shigella flexneri 2a-recombinant exoprotein A conjugate (69 urine samples) or meningoccal tetravalent control vaccines (4 urine samples). All the volunteers who lacked a significant response to S. sonnei LPS in serum also lacked such response in urine samples. Seventy-four percent of the volunteers with a significant IgA or IgG anti-LPS response in serum at convalescence or 14 days after vaccination showed a similar response in urine. The ratio of the titer of secretory protein bound to IgA anti-S. sonnei LPS in urine to that in serum was 303 times higher than the ratio of anti-S. sonnei LPS total IgA titer in urine to that in serum, indicating that the urine IgA is of secretory origin. These findings suggest the possible use of urinary Shigella LPS antibodies as markers of systemic and secretory immune responses after natural infection or vaccination. At this stage, because of its limited sensitivity, the detection by ELISA of Shigella LPS antibodies in urine cannot replace the same assay in serum as a definitive test in an individual with a negative result.

show abstract

“…Several vaccines or vaccine candidates exist against enteric bacteria that infect AIDS patients, e.g. Salmonella [56][57][58][59][60], Campylobacter [61] and Shigella [62][63][64], but not against M. avium-intracellulare. Promising oral vaccines have been developed against rotavirus [65][66][67][68], which is the most common viral enteric pathogen affecting HIV-infected children [3].…”

Section: Significancementioning

confidence: 99%

Induction and Expression of Intestinal Humoral Immunity in HIV-Infected Individuals: Prospects for Vaccination against Secondary Enteric Infections

Eriksson¹,

Kilander

Hagberg³

et al. 1998

Pathobiology

View full text Add to dashboard Cite

In view of the high incidence and severity of AIDS-related mucosal complications and secondary mucosal infections, we have evaluated the impact of HIV infection on the mucosal humoral immune status. By measuring the number of total and specific antibody-secreting cells in duodenal biopsies, we could show that HIV infection induces a pronounced polyclonal B-cell activation already in the early stages of the disease. Furthermore, we could document normal mucosal B-cell responses following oral vaccination, also in the late stages of the disease, and despite a lack of concomitant systemic responses. The relevance of these observations will be discussed with respect to the possibility of vaccinating HIV-infected individuals against secondary opportunistic infections.

show abstract

Safety and immunogenicity of the oral E. coli K12-S. flexneri 2a vaccine (EcSf2a-2) among Israeli soldiers

Cited by 9 publications

References 19 publications

Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: A single blind, partially randomized Phase I study

Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: A single blind, partially randomized Phase I study

Detection of antibodies to Shigella lipopolysaccharide in urine after natural Shigella infection or vaccination

Induction and Expression of Intestinal Humoral Immunity in HIV-Infected Individuals: Prospects for Vaccination against Secondary Enteric Infections

Contact Info

Product

Resources

About